​​July policy updates

August 5, 2022

​In July, Independence Blue Cross updated several policies. Published updates include:

  • 08.00.85m: Tocilizumab (Actemra®) for Intravenous Infusion. Effective date: July 18, 2022
  • 08.01.94: Nivolumab and relatlimab-rmbw (Opdualag™). Effective date: July 18, 2022

To view the latest medical and claim payment policy bulletins, visit the Medical and Claim Payment Policy P​ortal.

For important policy information related to COVID-19, visit the Commercial and Medicare Advantage News & Announcements sections of the portal.